{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:31:31Z","timestamp":1776817891500,"version":"3.51.2"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011790","name":"Xiangya Hospital, Central South University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600183"],"award-info":[{"award-number":["81600183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.bioorg.2022.106217","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:13:23Z","timestamp":1666311203000},"page":"106217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["CC1007, a small molecular compound, suppresses multiple myeloma via upregulation of Nur77"],"prefix":"10.1016","volume":"129","author":[{"given":"Shicong","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangsen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2356-4613","authenticated-orcid":false,"given":"Zhihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2022.106217_b0005","doi-asserted-by":"crossref","unstructured":"K.D. Miller, A. Goding Sauer, A.P. Ortiz, S.A. Fedewa, P.S. Pinheiro, G. Tortolero-Luna, D. Martinez-Tyson, A. Jemal, R.L. Siegel, Cancer statistics for hispanics\/latinos, 2018, CA Cancer J. Clin. 68 (2018) 425\u2013445, doi: 10.3322\/caac.21494.","DOI":"10.3322\/caac.21494"},{"key":"10.1016\/j.bioorg.2022.106217_b0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2022.106217_b0015","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrc.2017.63","article-title":"Evolutionary biology of high-risk multiple myeloma","volume":"17","author":"Pawlyn","year":"2017","journal-title":"Nat. Rev. Cancer."},{"key":"10.1016\/j.bioorg.2022.106217_b0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bioorg.2022.106217_b0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/nyas.12578","article-title":"The osteoblastic niche in the context of multiple myeloma","volume":"1335","author":"Toscani","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bioorg.2022.106217_b0030","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bioorg.2022.106217_b0035","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4161\/15592294.2014.983367","article-title":"Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma","volume":"9","author":"Mithraprabhu","year":"2014","journal-title":"Epigenetics."},{"key":"10.1016\/j.bioorg.2022.106217_b0040","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1038\/leu.2015.83","article-title":"Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma","volume":"29","author":"Kikuchi","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2022.106217_b0045","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/bjc.2013.392","article-title":"Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors","volume":"109","author":"Moreaux","year":"2013","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.bioorg.2022.106217_b0050","first-page":"84","article-title":"Farydak (panobinostat): first HDAC inhibitor approved for patients with relapsed multiple myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am. Health Drug Benefits."},{"key":"10.1016\/j.bioorg.2022.106217_b0055","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2022.106217_b0060","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nchembio.313","article-title":"Chemical phylogenetics of histone deacetylases","volume":"6","author":"Bradner","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2022.106217_b0065","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1093\/nar\/gks189","article-title":"Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2","volume":"40","author":"Jayathilaka","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2022.106217_b0070","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41419-020-02949-1","article-title":"A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7\/MEF2C interaction in BCR-ABL1(-) pre-B-ALL","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2022.106217_b0075","unstructured":"E. Sabattini, F. Bacci, C. Sagramoso, S.A. Pileri, WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview, Pathologica 102 (2010) 83\u201387."},{"key":"10.1016\/j.bioorg.2022.106217_b0080","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2184.2003.00266.x","article-title":"The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer","volume":"36","author":"Vermeulen","year":"2003","journal-title":"Cell Prolif."},{"key":"10.1016\/j.bioorg.2022.106217_b0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.canlet.2013.01.025","article-title":"A novel cyclinE\/cyclinA-CDK inhibitor targets p27(Kip1) degradation, cell cycle progression and cell survival: implications in cancer therapy","volume":"333","author":"Dai","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2022.106217_b0090","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.mcn.2010.01.012","article-title":"MEF-2 regulates activity-dependent spine loss in striatopallidal medium spiny neurons","volume":"44","author":"Tian","year":"2010","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.bioorg.2022.106217_b0095","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1038\/s41388-020-1158-y","article-title":"Nur77-activated lncRNA WFDC21P attenuates hepatocarcinogenesis via modulating glycolysis","volume":"39","author":"Guan","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2022.106217_b0100","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/gutjnl-2011-300783","article-title":"The orphan receptor TR3 suppresses intestinal tumorigenesis in mice by downregulating Wnt signalling","volume":"61","author":"Chen","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.bioorg.2022.106217_b0105","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm1579","article-title":"Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia","volume":"13","author":"Mullican","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2022.106217_b0110","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2013-08-518878","article-title":"NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomas","volume":"123","author":"Deutsch","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2022.106217_b0115","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1182\/blood-2006-11-056879","article-title":"Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma","volume":"109","author":"Luciano","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2022.106217_b0120","doi-asserted-by":"crossref","unstructured":"K. Dimopoulos, P. Gimsing, K. Gr\u00f8nb\u00e6k, The role of epigenetics in the biology of multiple myeloma, Blood Cancer J. 4 (2014) e207, doi: 10.1038\/bcj.2014.29.","DOI":"10.1038\/bcj.2014.29"},{"key":"10.1016\/j.bioorg.2022.106217_b0125","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2002-11-3514","article-title":"Molecular sequelae of histone deacetylase inhibition in human malignant B cells","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2022.106217_b0130","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12185-016-2008-0","article-title":"Histone deacetylase inhibitors in multiple myeloma: from bench to bedside","volume":"104","author":"Harada","year":"2016","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bioorg.2022.106217_b0135","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2022.106217_b0140","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2022.106217_b0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-018-0654-9","article-title":"Histone deacetylase 6 in cancer","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2022.106217_b0150","doi-asserted-by":"crossref","unstructured":"D.T. Vogl, N. Raje, S. Jagannath, P. Richardson, P. Hari, R. Orlowski, J.G. Supko, D. Tamang, M. Yang, S.S. Jones, C. Wheeler, R.J. Markelewicz, S. Lonial, Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma, Clin. Cancer Res. 23 (2017) 3307\u20133315, doi: 10.1158\/1078-0432.CCR-16-2526.","DOI":"10.1158\/1078-0432.CCR-16-2526"},{"key":"10.1016\/j.bioorg.2022.106217_b0155","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1080\/10428194.2017.1312383","article-title":"MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy","volume":"58","author":"Colomer-Lahiguera","year":"2017","journal-title":"Leuk. Lymphoma."},{"key":"10.1016\/j.bioorg.2022.106217_b0160","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1111\/bjh.16418","article-title":"High expression of myocyte enhancer factor 2C predicts poor prognosis for adult acute myeloid leukaemia with normal karyotype","volume":"189","author":"Xu","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bioorg.2022.106217_b0165","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/sj.leu.2405067","article-title":"MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines","volume":"22","author":"Nagel","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2022.106217_b0170","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0092-8674(04)00162-X","article-title":"Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77\/TR3","volume":"116","author":"Lin","year":"2004","journal-title":"Cell"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682200623X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682200623X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:46:42Z","timestamp":1758617202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682200623X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":34,"alternative-id":["S004520682200623X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.106217","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CC1007, a small molecular compound, suppresses multiple myeloma via upregulation of Nur77","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.106217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106217"}}